Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension

National Taiwan University

Status: Withdrawn

Conditions: Primary and Secondary Pulmonary Hypertension

Treatments: Drug: type-5 phosphodiesterase Inhibitor (Sildenafil)

Study type: Interventional

Funder types: Other

Identifiers

NCT00155714

9100017321

Details and patient eligibility

About

The aim of this trial is to evaluate the efficacy of type-5 phosphodiesterase inhibitors (sildenafil) in primary and secondary pulmonary hypertension

Full description

Patients with primary and secondary pulmonary hypertension will be recruited and admitted to the ICUs of the National Taiwan University Hospital. Each patient will undergo Swan-Ganz catheterization and hemodynamic monitoring during administration of sildenafil. Efficacy of inhaled NO and Iloprost will also be compared.

Enrollment: 20 estimated patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:Patients with primary and secondary pulmonary arterial hypertension

Exclusion Criteria:Unstable patients or patients with allergy to sildenafil

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)